Insulin; Related Peptides Patents (Class 530/303)
-
Patent number: 8691940Abstract: Modified relaxin polypeptides and their uses are provided. In one aspect, the disclosure provides a relaxin polypeptide comprising one or more non-naturally encoded amino acids. The polypeptide may be linked to a linker, polymer, or biologically active molecule. The serum half-life of the relaxin polypeptide may be enhanced relative to the unconjugated form. In another aspect, the disclosure provides methods of treating a patient having a disorder modulated by relaxin.Type: GrantFiled: August 17, 2011Date of Patent: April 8, 2014Assignee: Ambrx, Inc.Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
-
Publication number: 20140086994Abstract: The invention provides an apparatus for forming fine particles of a substance in a precipitation chamber, in which the apparatus has means to convey the fine particles from the precipitation chamber to at least one particle collection chamber, downstream of the precipitation chamber, the particle collection chamber having an inlet and an outlet separate from the inlet. The invention also provides a method of forming fine particles of a substance, the method comprising contacting a non-gaseous fluid containing the substance with a dense fluid to expand the non-gaseous fluid in a precipitation chamber, conveying a resulting mixture of fluid and the fine particles from the precipitation chamber to a collection chamber, the collection chamber having an inlet and an outlet separate from the inlet.Type: ApplicationFiled: December 4, 2013Publication date: March 27, 2014Applicant: MAP Pharmaceuticals, Inc.Inventors: Neil Russell Foster, Hubert Leonardus Regtop, Fariba Dehghani
-
Publication number: 20140073564Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.Type: ApplicationFiled: August 22, 2013Publication date: March 13, 2014Applicant: Novo Nordisk A/SInventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Jaanos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
-
Patent number: 8669227Abstract: The invention relates to a complex between an insulin and a polysaccharide comprising carboxyl functional groups, said polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, said phenylalanine derivative being chosen from the group consisting of phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide and ethylbenzylamine or from phenylalanine esters, and said insulin being either a human insulin or an insulin analog. The invention also relates to a pharmaceutical composition comprising at least one complex according to the invention, especially in the form of an injectable solution.Type: GrantFiled: March 29, 2010Date of Patent: March 11, 2014Assignee: AdociaInventors: Olivier Soula, Remi Soula, Gerard Soula
-
Publication number: 20140057841Abstract: Disclosed is a recombinant human insulin or analog conjugate thereof. Said conjugate is formed by connecting the ?-amino group of lysine 29 of the B chain to activated polyethylene glycol by means of an amide bond. Further disclosed is a method of preparing said conjugate, a pharmaceutical compound, and a use for said conjugate in preparing medication for treating Type 1 and Type 2 diabetes.Type: ApplicationFiled: March 19, 2012Publication date: February 27, 2014Applicant: Chongqing Fagen Biomedical Inc.Inventors: Kai Fan, Yu Cao, Yong Chen, Hongliang Li, Hairong Chen, Ying Wan
-
Patent number: 8658423Abstract: This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer.Type: GrantFiled: September 14, 2012Date of Patent: February 25, 2014Assignee: Cancer Research Technology LimitedInventors: Andrew Bassim Hassan, Oliver Zaccheo, Stuart Prince
-
Publication number: 20140046020Abstract: Metabolic Activation Therapy (MAT®) is a procedure which uses intravenous insulin pulses administered with oral glucose to deliver an insulin treatment regimen that improves the biochemistry and physiology of diabetic and non-diabetic individuals. If implemented preoperatively to patients with a history of hyperglycemia who undergo surgical and other stress inducing procedures, including those requiring hospitalization, postoperative glycemic control is improved and the insulin required during and after the operation is decreased with no increase in incidents of hypoglycemia. If implemented in patients not previously known to have diabetes but who are at high risk for becoming hyperglycemic in response to said surgical/medical procedures known to be physiologically stressful, it results in increased insulin sensitivity, lower circulating glucose levels post procedure, and shorter length of hospital stay.Type: ApplicationFiled: March 22, 2012Publication date: February 13, 2014Inventor: Thomas T. Aoki
-
Publication number: 20140045216Abstract: Polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) are disclosed. Also disclosed are fusion proteins comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide. Also disclosed are protein expression vectors comprising a promoter operably linked to a first DNA sequence encoding a signal sequence comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) and a second DNA sequence encoding a heterologous polypeptide fused in frame to the first DNA sequence. Further disclosed are methods of producing a polypeptide comprising expressing a fusion protein comprising a polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide and recovering the heterologous polypeptide.Type: ApplicationFiled: November 22, 2011Publication date: February 13, 2014Applicant: Callidus Biopharma, Inc.Inventor: Hung Do
-
Publication number: 20140037699Abstract: In one aspect, the disclosure provides a conjugate comprising an insulin molecule having an A-chain and a B-chain; an affinity ligand covalently bound to the A-chain; and a monovalent glucose binding agent covalently bound to the B-chain, wherein the affinity ligand competes with glucose for non-covalent binding with the monovalent glucose binding agent. In the absence of glucose, the monovalent glucose binding agent binds the affinity ligand to produce a “closed” inactive form of the insulin molecule. When free glucose is added, it competes with the affinity ligand for binding with the monovalent glucose binding agent to produce an “open” active form of the insulin molecule. The monovalent glucose binding agent and affinity ligand are covalently bound to the insulin molecule. The disclosure also provides methods of using these conjugates and methods of making these conjugates. In another aspect, the disclosure provides exemplary conjugates.Type: ApplicationFiled: October 17, 2013Publication date: February 6, 2014Applicant: SmartCells, Inc.Inventors: Todd C. Zion, Thomas M. Lancaster
-
Patent number: 8642737Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: GrantFiled: July 29, 2011Date of Patent: February 4, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling
-
Patent number: 8642008Abstract: To provide a molecular probe for imaging of pancreatic islets. A molecular probe for use in imaging of pancreatic islets is provided. The molecular probe includes any one of the following polypeptides: polypeptides represented by the following formulae (1), (5), and (9); and polypeptides having homology with the foregoing polypeptides: Z-DLSXQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2? (1) Z-DLSKQMEEEAVRLFIEWLXNGGPSSGAPPPS-NH2? (5) B-DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2? (9) where X in the formulae (1) and (5) and B- in the formula (9) indicate that an amino group is labeled with a group represented by the formula (I) below having an aromatic ring, wherein A represents either an aromatic hydrocarbon group or an aromatic heterocyclic group, R1 represents a substituent that contains radioactive iodine, R2 represents either a hydrogen atom or a substituent different from that represented by R1, and R3 represents any one of a bond, a methylene group, and an oxymethylene group.Type: GrantFiled: August 31, 2010Date of Patent: February 4, 2014Assignees: Kyoto University, ARKRAY, Inc.Inventors: Nobuya Inagaki, Hideo Saji, Kentaro Toyoda, Hiroyuki Kimura, Yu Ogawa, Konomu Hirao, Kenji Nagakawa, Hirokazu Matsuda
-
Publication number: 20140031279Abstract: The present invention relates to human insulin analogues containing a substituting cysteine, to human insulin derivatives containing a PEGylated substituting cysteine and methods of making such. The compounds of the invention may be useful for the treatment of diabetes.Type: ApplicationFiled: March 15, 2012Publication date: January 30, 2014Applicants: UNIVERSITY OF COPENHAGEN, NOVO NORDISK A/SInventors: Tine Nygaard Vinther, Thomas Boerglum Kjeldsen, Frantisek Hubalek, Knud J. Jensen
-
Patent number: 8618051Abstract: The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and antibodies, and methods for the prevention and treatment of conditions, diseases and disorders that would be improved, eased, or lessened by the administration of a composition of the invention, including but not limited to glucose metabolism diseases.Type: GrantFiled: August 2, 2010Date of Patent: December 31, 2013Assignee: Auckland Uniservices LimitedInventors: Christina Maree Buchanan, Garth James Smith Cooper
-
Patent number: 8618049Abstract: Compositions and methods related to ester insulin or derivatives thereof are provided. The compositions include GluA4-ThrB30 ester insulin, in which side chains of GluA4 and ThrB30 of native human insulin or an insulin analogue such as insulin lispro are covalently linked via a single ester bond. The ester insulin is efficiently folded, forming the desired disulfides. The ThrB30-GluA4 ester bond can be cleaved in vitro or in vivo to give the desired folded insulin with full biological activity. The ester insulin is readily prepared by total chemical synthesis, and amendable to cost-effective, large scale manufacturing. Also provided are pharmaceutical compositions and kits for use in practicing the subject methods. Also provided are methods of using the subject compositions and kits in the treatment of a variety of different disease conditions, particularly glucose metabolic disorders such as diabetes and obesity.Type: GrantFiled: September 7, 2010Date of Patent: December 31, 2013Inventors: Stephen B. H. Kent, Youhei Soma
-
Patent number: 8618048Abstract: New biosynthetic analogues of recombined human insulin of prolonged therapeutical activity, which can find place in prophylactic and treatment of diabetes.Type: GrantFiled: July 4, 2009Date of Patent: December 31, 2013Assignee: Instytut Biotechnologii I AntybiotykówInventors: Piotr Borowicz, Andrzej Plucienniczak, Jerzy Mikolajczyk, Tadeusz Glabski, Dariusz Kurzynoga, Diana Mikiewicz-Sygula, Anna Wojtowicz-Krawiec, Marcin Zielinski, Malgorzata Kesik-Brodacka, Violetta Adamczewska-Cecuda, Iwona Sokolowska, Grazyna Plucienniczak, Dorota Stadnik, Jaroslaw Antosik, Jacek Pstrzoch, Justyna Bernat, Wojciech Slawinski, Tomasz Pawlukowiec, Jacek Stepniewski, Monika Bogiel
-
Publication number: 20130338064Abstract: Provided are an insulin-lipid complex, a preparation method thereof, and a formulation thereof. The insulin-lipid complex is prepared by compounding insulin and a lipid material in an organic solvent system containing a low boiling point acid, and drying. The mass ratio of insulin to the lipid material is 1:3˜1:20. An oil solution of the insulin-lipid complex and vesicles containing insulin are further provided.Type: ApplicationFiled: July 14, 2011Publication date: December 19, 2013Applicant: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Yuling Liu, Cuiping Zhou, Zhihui Song, Lin Li, Hongliang Wang, Xuejun Xia, Renyun Wang, Wujun Dong, Dujia Jin
-
Patent number: 8603529Abstract: In one aspect, the disclosure provides cross-linked materials that include multivalent polynucleotide aptamers that bind a target molecule; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with the target molecule for binding with the aptamers and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between aptamers and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of the target molecule. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label. The drug, detectable label and affinity ligands may be covalently or non-covalently bound to the conjugate framework.Type: GrantFiled: January 27, 2010Date of Patent: December 10, 2013Assignee: Smartcells, Inc.Inventors: Todd C. Zion, Thomas M. Lancaster
-
Publication number: 20130296528Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: ApplicationFiled: November 22, 2011Publication date: November 7, 2013Applicant: ELASTAGEN PTY LIMITEDInventor: Jens Sommer-Knudsen
-
Patent number: 8575096Abstract: The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.Type: GrantFiled: August 12, 2008Date of Patent: November 5, 2013Assignee: Novo Nordisk A/SInventors: Helle Birk Olsen, Thomas Børglum Kjeldsen, Per Balschmidt, Tine Glendorf, Svend Havelund
-
Patent number: 8568781Abstract: Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein peptides are bound to or associated with the nanoparticles.Type: GrantFiled: June 10, 2011Date of Patent: October 29, 2013Assignee: Midatech LimitedInventors: Thomas Rademacher, Phillip Williams, Christof Bachmann, Africa Garcia Barrientos, Esther de Torres Dominguez, Javier del Campo Menoyo
-
Publication number: 20130280783Abstract: Provided herein are polymeric ?-hydroxy aldehyde or ?-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the ?-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol.Type: ApplicationFiled: June 24, 2013Publication date: October 24, 2013Inventors: Sean M. CULBERTSON, Xiaoming Shen, Antoni Kozlowski, Samuel P. McManus
-
Patent number: 8563685Abstract: Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.Type: GrantFiled: October 20, 2009Date of Patent: October 22, 2013Assignee: Biocon LimitedInventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Leo Pavliv, Karen Polowy, Monica Puskas, Nnochiri N. Ekwuribe
-
Publication number: 20130273173Abstract: Embodiments provide apparatus and methods for delivering solid form medications such as pellets to various locations in the body. One embodiment provides an apparatus for in vivo delivery of medication pellets comprising a housing including a port, a pellet-containing belt disposed in the housing, and a mechanism for transferring the pellets from the belt to a delivery site (DS) outside the housing. Each pellet contains a dose of drug to treat a medical condition. An elongate member is coupled to the housing and includes a lumen for pellet delivery, a proximal end coupled to the port and a distal end positioned at the DS. The pellet can be delivered to the DS at regular intervals or responsive to a detected biological event. Embodiments of the invention are particularly useful for delivering medication to treat a medical condition over an extended period without requiring a patient to take external medication.Type: ApplicationFiled: October 4, 2012Publication date: October 17, 2013Applicant: InCube Labs, LLCInventor: Mir Imran
-
Patent number: 8530412Abstract: The present invention provides a liquid composition, as an ejection liquid used for stably ejecting liquid droplets, including at least one kind of a protein and a peptide, and a compound having a betaine skeleton by application of thermal energy to the liquid; a method of making droplets form the liquid; and an ejection method and an ejection device suitable for utilizing protein liquid droplets. By adding a compound having a betaine skeleton to an aqueous solution of at least one kind of a protein and a peptide, the liquid composition is improved in stability for ejection by application of thermal energy. Further, a surfactant may be further added to the liquid composition containing the compound having a betaine skeleton, and in this case the effect of stable ejection can be obtained.Type: GrantFiled: January 7, 2011Date of Patent: September 10, 2013Assignee: Canon Kabushiki KaishaInventors: Masaru Sugita, Yohei Masada, Hideki Kaneko
-
Patent number: 8530620Abstract: The present invention relates to reagents and methods for [18F]-fluorination of biomolecules, particularly of peptides. The resultant 18F-labelled compounds are useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET).Type: GrantFiled: March 22, 2010Date of Patent: September 10, 2013Assignee: GE Healthcare LimitedInventors: Dag Erlend Olberg, Joseph Maduabuchi Arukwe
-
Publication number: 20130217621Abstract: A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The supramolecular assemblies disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising the supramolecular assembly.Type: ApplicationFiled: March 18, 2013Publication date: August 22, 2013Inventors: Avadhesha Surolia, Sarika Gupta, Mahendra Pal Singh, Tandrika Chattopadhyay
-
Patent number: 8512932Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.Type: GrantFiled: September 22, 2011Date of Patent: August 20, 2013Assignee: MannKind CorporationInventors: Bryan R. Wilson, Marshall Grant
-
Publication number: 20130203665Abstract: Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs.Type: ApplicationFiled: June 16, 2011Publication date: August 8, 2013Inventors: Richard D. DiMarchi, Julia Azriel, Zach Kaur, Jonathan Meyers, Todd Parody, Yan Zhao
-
Patent number: 8501440Abstract: A fibrillation-resistant insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A chain sequence or an analogue thereof and an insulin B chain sequence or an analogue thereof connected by a polypeptide of 4-10 amino acids. The fibrillation-resistant insulin analogue preferably displays less than 1 percent fibrillation with incubation at 37° C. for at least 21 days. A single-chain insulin analogue displays greater in vitro insulin receptor binding than normal insulin while displaying less than or equal binding to IGFR than normal insulin. The fibrillation-resistant insulin may be used to treat a patient using an implantable or external insulin pump, due to its greater fibrillation resistance.Type: GrantFiled: May 16, 2012Date of Patent: August 6, 2013Assignee: Case Western Reserve UniversityInventor: Michael Weiss
-
Publication number: 20130190475Abstract: The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: I wherein each of X, Alk1, Alk2, and W are as defined and described herein.Type: ApplicationFiled: July 22, 2011Publication date: July 25, 2013Applicant: SMARTCELLS, INC.Inventors: Zhiyu Chen, Thomas M. Lancaster, Todd C. Zion
-
Publication number: 20130190476Abstract: The present disclosure provides recombinantly expressed insulin polypeptides that comprise an N-linked glycan motif. The N-linked glycan motif is not present in wild-type insulins and enables the recombinant expression of glycosylated insulin polypeptides (e.g., in yeast cells). Based on results obtained with synthetic glycosylated insulin conjugates we predict that when these recombinant glycosylated insulin polypeptides are administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the glycosylated insulin polypeptide will be sensitive to serum concentrations of glucose (or an exogenous saccharide such as alpha-methyl mannose). Exemplary insulin polypeptides, polynucleotides encoding these insulin polypeptides, glycosylated insulin polypeptides, pharmaceutical formulations and sustained release formulations are provided in addition to methods of use and preparation.Type: ApplicationFiled: July 22, 2011Publication date: July 25, 2013Inventors: Thomas M. Lancaster, Sylaja Murikipudi, Rassol Laleau, Todd C. Zion
-
Patent number: 8486889Abstract: This invention involves compositions and method of using of therapeutic agents for pain relief for the treatment and prevention of disorders associated with endothelial dysfunction, the cause of inflammation, atherosclerosis, cardiovascular disease, diabetes, hypertension, asthma and stroke in mammals comprising anti-inflammatory agents, epinephrine, insulin, anti-viral agents and dietary supplements.Type: GrantFiled: September 1, 2012Date of Patent: July 16, 2013Assignee: Advanced Medical InstrumentsInventor: Edward J Petrus
-
Publication number: 20130178414Abstract: The present invention is related to human insulin containing additional disulfide bonds and methods of making such.Type: ApplicationFiled: June 21, 2011Publication date: July 11, 2013Applicant: NOVO NORDISK A/SInventors: Frantisek Hubalek, Tine Nygaard Vinther, Thomas Boerglum Kjeldsen, Svend Ludvigsen
-
Publication number: 20130172247Abstract: The present invention is related to insulin analogues containing additional disulfide bonds and methods of making such.Type: ApplicationFiled: June 21, 2011Publication date: July 4, 2013Applicant: NOVO NORDISK A/SInventors: Svend Ludvigsen, Frantisek Hubalek, Thomas Boerglum Kjeldsen
-
Publication number: 20130172204Abstract: The invention concerns a first diagnostic method for glaucoma based on an analysis of autoimmune reactivity in body fluids against at least one sample of at least partially purified ocular antigens, wherein the autoimmune reactivity against individual antigens is measured and transformed into a glaucoma score to determine the diagnostic result. Further aspects of the invention include antigen carrying elements carrying at least one sample of the at least partially purified ocular antigens and kits for diagnosis of glaucoma. Further aspects include methods of collecting a body fluid such as tears for the use in the diagnostic method for glaucoma. Yet further aspects include ocular antigens serving as diagnostic markers and/or for preparing pharmaceutical compositions for treatment of glaucoma.Type: ApplicationFiled: April 13, 2011Publication date: July 4, 2013Applicant: M-LAB AGInventors: Franz Grus, Nils Boehm, Norbert Pfeiffer, Katharina Bell
-
Patent number: 8476232Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.Type: GrantFiled: August 21, 2012Date of Patent: July 2, 2013Assignee: Hoffman-La Roche Inc.Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar, Hans-Joachim Schoenfeld
-
Patent number: 8476228Abstract: The present invention relates to insulin derivatives having a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.Type: GrantFiled: October 14, 2011Date of Patent: July 2, 2013Assignee: Novo Nordisk A/SInventors: János Tibor Kodra, Patrick William Garibay, Thomas Hoeg-Jensen, Ib Jonassen, Peter Madsen, Tina Møller Tagmose
-
Publication number: 20130157938Abstract: The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such.Type: ApplicationFiled: June 21, 2011Publication date: June 20, 2013Applicant: NOVO NORDISK A/SInventors: Peter Madsen, Frantisek Hubalek, Thomas Boerglum Kjeldsen, Svend Ludvigsen
-
Patent number: 8455204Abstract: Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and/or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of, or the making of medicaments for the treatment of, metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like.Type: GrantFiled: May 27, 2009Date of Patent: June 4, 2013Assignee: Energesis Pharmaceuticals, Inc.Inventors: Olivier D. Boss, Jean-Paul Giacobino
-
Publication number: 20130131310Abstract: The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: (I) wherein each of X, Alk, and W are as defined and described herein.Type: ApplicationFiled: July 22, 2011Publication date: May 23, 2013Inventors: John Kane, Thomas M. Lancaster, Todd C. Zion
-
Publication number: 20130123171Abstract: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: ApplicationFiled: June 23, 2011Publication date: May 16, 2013Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORAInventors: Richard D. DiMarchi, Binbin Kou, Shujiang Cheng
-
Patent number: 8440616Abstract: The present invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single administrations are administered to the patient substantially contemporaneously each day.Type: GrantFiled: March 12, 2012Date of Patent: May 14, 2013Assignee: Tercica, Inc.Inventor: Gillian Clark
-
Patent number: 8436136Abstract: A complex comprising at least one heat shock protein (HSP) and at least one peptide selected from the group consisting of R1-QXRAA-R2 with R1=peptide with 1-10 amino acids R2=peptide with 1-10 amino acids X=K or R GFFYTPK (insulin 23-29) SEQ ID No 1 GFFYTPKT (insulin 23-30) SEQ ID No 2 IYPPNANK (DER p1) SEQ ID No 3 GIEYIQHNGVVQESYYR (DER P1) SEQ ID No 4 ASTTTNYT (gp120 of HIV) SEQ ID No 5 DYEYLINVIHAFQYV (PLP 56-70) SEQ ID No 6 EKLIETYFSKNYQDYEYLINVI (PLP 43-64) SEQ ID No 7 KTTICGKGLSATVT (PLP 104-117) SEQ ID No 8 HSLGKWLGHPDKF (PLP 139-151 C140 ô S140) SEQ ID No 9 PRHPIRVELPCRISP (MOG 8-22) SEQ ID No 10 DEGGYTCFFRDHSYQ (MOG 92-106) SEQ ID No 11 Ac-ASQKRPSQRHG (MBP ac1-11) SEQ ID No 12 TGILDSIGRFFSG (MBP 35-47) SEQ ID No 13 VHFFKNIVTPRTP (MBP 89-101) SEQ ID No 14 HCLGKWLGHPDKF (PLP 139-151) SEQ ID No 15 MEVGWYRSPFSRVVHLYRNGK (MOG) SEQ ID No 16 QKRAAYDQYGHAAFE (E. Coli DnaJ) SEQ ID No. 17 QKRAAVDTYCRHNYG (HLA DRB1*0401) SEQ ID No. 18 QRRAAYDQYGHAAFE SEQ ID No. 19 and QRRAAVDTYCRHNYG SEQ ID No. 20.Type: GrantFiled: May 18, 2004Date of Patent: May 7, 2013Assignee: Biotech Tools S.A.Inventors: Frederic Henot, Thierry Legon, Isabelle Galy-Fauroux, Jean Duchateau
-
Publication number: 20130096057Abstract: The subject matter of this invention is directed towards chemically and thermodynamically stable single-chain insulin (SCI) analogues that are resistant to deamidation and fibrillation. The invention further discloses improved methods for the recombinant expression, purification and refolding of SCI.Type: ApplicationFiled: October 16, 2012Publication date: April 18, 2013Applicant: AMIDEBIO LLCInventor: AmideBio LLC
-
Publication number: 20130096050Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an a-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.Type: ApplicationFiled: April 22, 2011Publication date: April 18, 2013Applicant: Longevity Biotech, Inc.Inventor: Scott J Shandler
-
Publication number: 20130091604Abstract: A promoter for transformation of a plant, in particular an aboveground organ specific promoter, a recombinant plant expression vector including the promoter, a method of producing target protein using the recombinant plant expression vector, target protein produced by the method, a method of producing a transformed plant using the recombinant plant expression vector, a transformed plant produced by the same, and a seed of the plant.Type: ApplicationFiled: October 8, 2012Publication date: April 11, 2013Applicant: MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATIInventor: MYONGJI UNIVERSITY INDUSTRY AND ACADE
-
Patent number: 8410048Abstract: The invention relates to a method for producing a type of insulin by genetically engineering a precursor thereof and converting said precursor to the respective insulin in an enzyme-catalyzed ligation reaction with lysine amide or arginine amide, or by lysine or arginine which is modified by protective groups, and optionally subsequent hydrolysis.Type: GrantFiled: January 7, 2009Date of Patent: April 2, 2013Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Frank Zocher
-
Patent number: 8383585Abstract: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.Type: GrantFiled: July 17, 2009Date of Patent: February 26, 2013Assignee: IKFE Institut fur Klinische Forschung und Entwicklung GmbHInventors: Andreas Pfuetzner, Thomas Forst
-
Publication number: 20130040884Abstract: Novel polypeptide derivatives having protracted profile of action.Type: ApplicationFiled: March 22, 2012Publication date: February 14, 2013Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
-
Publication number: 20130034547Abstract: A chimeric therapeutic polypeptide of a pre-existing therapeutic polypeptide is disclosed, as are a method of enhancing folded stabilization and a pharmaceutical composition of the glycosylated chimer. The pre-existing and chimeric polypeptides have substantially the same length, substantially the same amino acid residue sequence, and exhibit at least one tight turn containing a sequence of four to about seven amino acid residues in which at least two amino acid side chains extend on the same side of the tight turn and are within less than about 7 ? of each other. The chimeric therapeutic polypeptide has the sequon Aro-(Xxx)n-(Zzz)p-Asn-Yyy-Thr/Ser (SEQ ID NO:001) within that tight turn sequence such that the side chains of the Aro, Asn and Thr/Ser amino acid residues project on the same side of the turn and are within less than about 7 ? of each other. That sequon is absent from the pre-existing therapeutic polypeptide.Type: ApplicationFiled: August 2, 2012Publication date: February 7, 2013Inventors: Jeffery W. Kelly, Joshua L. Price, Elizabeth K. Culyba, Evan T. Powers